SLC5A2 and type 2 diabetes mellitus: Studies have suggested that the SGLT2 inhibitor empagliflozin induces glycosuria in patients with T2D, resulting in decreasing plasma glucose and insulin levels while increasing fasting and post-meal glucagon concentrations [98].